Are Quaternary Ammonium Compounds, the Workhorse Disinfectants, Effective against Severe Acute Respiratory Syndrome-Coronavirus-2?

Cassandra L. Schrank, Kevin P. C. Minbiole,* and William M. Wuest*

ABSTRACT: A novel virus named Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) emerged from Wuhan, China in late 2019. Since then, the virus has quickly spread worldwide, leading the World Health Organization to declare it as a pandemic; by the end of April 2020, the number of cases exceeded 3 million. Due to the high infectivity rate, SARS-CoV-2 is difficult to contain, making disinfectant protocols vital, especially for essential, highly trafficked areas such as hospitals, grocery stores, and delivery centers. According to the Centers for Disease Control and Prevention, best practices to slow the spread rely on good hand hygiene, including proper handwashing practices as well as the use of alcohol-based hand sanitizers. However, they provide warning against sanitizing products containing benzalkonium chloride (BAC), which has sparked concern in both the scientific community as well as the general public as BAC, a common quaternary ammonium compound (QAC), is ubiquitous in soaps and cleaning wipes as well as hospital sanitation kits. This viewpoint aims to highlight the outdated and incongruous data in the evaluation of BAC against the family of known coronaviruses and points to the need for further evaluation of the efficacy of QACs against coronaviruses.

In the late months of 2019 leading into January of 2020, a novel virus emerged in Wuhan, China and was given the name Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2; Figure 1); the associated disease was termed COVID-19 (CO-rona-VI-rus D-isease 2019, Figure 1).1−3 The virus quickly spread across Europe and into North and South America, leading the World Health Organization (WHO) to declare it as a pandemic on March 11, 2020, with over 118 000 infections in over 114 countries at that time.4 Seven weeks later, the number of cases exceeded 3 million worldwide.5 SARS-CoV-2 is a part of the family of viruses known as Coronaviridae, which have led to previous coronavirus outbreaks: a SARS-CoV outbreak in 2002 and a Middle East Respiratory Syndrome (MERS)-CoV outbreak from 2012 to 2015.6,7,9−13 These three viral outbreaks have yielded similar symptoms, including shortness of breath, fever, coughing, and headaches. Although Coronaviridae is not new to the human population, SARS-CoV-2 is a larger threat as it has a much higher reproduction number ($R_0$) than previous coronavirus strains, meaning that the number of cases generated by one infected person is higher than previous outbreaks.9−13 This, coupled with longer incubations times, latent infections, and delayed symptoms, makes the virus difficult to contain.

Because of this, there is an urgent need for appropriate disinfection protocols to slow the spread of COVID-19. According to the Centers for Disease Control and Prevention (CDC), the most effective way to reduce COVID-19 infectivity rates is to practice appropriate hand hygiene, specifically employing proper handwashing with warm water and soap for a minimum of 20 s and avoiding touching one’s face.14 In addition, the CDC advocates for the use of alcohol-based hand sanitizers (ABHS) but provides warning about products containing benzalkonium chloride (BAC), stating: “Benzalkonium chloride, along with both ethanol and isopropanol, is deemed eligible by the FDA for use in the formulation of healthcare personnel hand rubs. However, available evidence indicates benzalkonium chloride has less reliable activity against coronavirus than either of the alcohols.”13

As BAC and related disinfectants are ubiquitous, found not only in soaps but also in cleaning wipes and hospital sanitation kits, the need for a reevaluation of the efficacy of these disinfectants against coronaviruses is vital.

Figure 1. Cartoon representation of SARS-CoV-2 viral structure. Figure made in Biorender.
kits, knowing their efficacy against SARS-CoV-2 is imperative to address the spread of the virus. The CDC goes on to reference a recent review, published in the Journal of Hospital Infection by Kampf et al., that tabulated the results of previous studies investigating how long viruses within the same family (MERS-CoV, SARS-CoV, and endemic human coronavirus) can exist on surfaces ranging from steel and plastic to disposable gowns and surgical gloves. Overall, it was reported that this class of virus can persist on inanimate objects with a wide range of times from 2 to 8 h (paper and aluminum) to ≤5 days (plastic, ceramic, and others). Since the publication of this and other reports, the scientific community has debated the length of time SARS-CoV-2 can persist on inanimate objects, with some reporting SARS-CoV-2 RNA on surfaces after >14 days.

With survival times varying among surface types, guidelines for best disinfectant practices are vital, most notably for essential work locations, including hospitals, grocery stores, and delivery centers, that together face higher traffic and risk rate than other locations. Currently, the CDC offers limited guidelines for surface disinfectants in the face of COVID-19. However, both the scientific community and general public have deferred to the article mentioned above for guidance in best practices, as it also includes a table of previous reports on the ability of common disinfectants to eradicate this family of viruses. The disinfectants in their literature review include two alcohols (ethanol and propanol), sodium hypochlorite, peroxides, aldehydes (formaldehyde and glutaraldehyde), two different types of quaternary ammonium compounds (BAC, 1 and didecyldimethylammonium chloride, 2; Figure 2), and several others. It is from this data table that the CDC provided its recommendations on ABHS and regarded BAC, a common quaternary ammonium compound (QAC), as ineffective at killing the virus. The pertinent data was based on a suspension-based assay found in an article by Wood and Payne in 1998 (Table 1, ref 19).

Beyond the use of BAC as a hand sanitizing agent, Kampf and coworkers also provided one example of BAC as a surface disinfectant from an article by Sattar et al. in 1989 with an active concentration of 0.04% w/v on a steel surface, showing it to also be ineffective at reducing the viral loading of HCoV (endemic human coronavirus) after 1 min exposure (Table 1). Combining this with the suspension assay result has sparked debate and worry as QACs, specifically BAC, are the active ingredients found in many household disinfecting wipes and sprays and are also used as additives in various soaps and nonalcohol-based hand sanitizers. This is due to their ability to eradicate surface bacteria and common viruses such as influenza by disrupting their phospholipid membrane (Figure 3).

Despite the current reluctance of the CDC to endorse a BAC-based hand sanitizer against COVID-19, the research backing the stance is neither current nor uniformly asserted. In particular, the disinfectant concentrations in the reports discussed herein are inconsistent, with broad ranges of applied QACs from 0.00175 to 1.5% w/v (Table 1, Figure 4). Additionally, the type of analysis varied widely. Most studies utilized suspension-based assays in which the virus was suspended in minimal media, but the contents of the media varied with concentrations and types of organic loading, added salt concentrations, as well as added antibiotics. For surface evaluations, some analyses utilized quantitative carrier tests (QCTs) with stainless steel discs as carriers of viral loads, while others simply described evaluating surface contamination but lacked details for reproducibility. It is the goal of this viewpoint to shed light on more recent data regarding the activity of BAC against coronaviruses, point out the disparities between available research, and draw attention to the need for further research into QACs. There is a need to not only broaden our understanding of the effectiveness of BAC against SARS-CoV-2 but also design and develop improved QACs for future infection control.

Based on another article briefly mentioned in Kampf et al., the work performed by Pratelli in Zoonoses and Public Health analyzed the effectiveness of QACs against Canine Coronavirus (CCoV), another family member within Coronaviridae. Although these results pertain to CCoV, it is within the same family as SARS-CoV-2 and should aid in evaluating the efficacy of QACs. Pratelli utilized a suspension-based assay, suspending cell cultures in Eagle’s minimal essential medium and supplementing with 10% fetal bovine serum. The report found that DDAC was able to reduce the viral loading of CCoV by >4.0 log_{10} after 3 day exposure corresponding to greater >99.99% clearance (Table 1). Conversely, BAC was unable to reduce the viral loading (3.0 log_{10}), but the author does note that both agents caused significant morphological damage to the virus.

Within a 2004 article by Ansaldi et al. in the Journal of Preventive Medicine and Hygiene, the authors analyzed the efficacy of the same group of disinfectants described by Kampf et al. against SARS-CoV within a 1 mL salt solution (concentration or identity of salt not specified) with a standard concentration of cell culture. Each replicate was exposed to 2 mL solutions of disinfectant with recommended disinfectant concentrations, e.g. BAC = 1% w/v. Interestingly, it was found that BAC did not significantly damage the cell monolayer but was able to reduce the replication of SARS-CoV after 5 min exposure (Table 1). However, after 30 min exposure to BAC, reverse transcriptase-polymerase chain reaction (RT-PCR) found SARS-CoV RNA still present on the surface. This result was consistent against each type of disinfectant analyzed (ethanol, BAC, sodium hypochlorite, etc.) as well as against three types of viruses tested (influenza, respiratory syncytial virus, and SARS-CoV). Therefore, it begs the question of whether intact RNA alone is an infective agent of SARS-CoV and SARS-CoV. This question remains unanswered and makes it difficult to appropriately evaluate efficacy of disinfectants across analyses.

Figure 2. Chemical structures of QACs reviewed in ref 15.
Table 1. Ability of Different QACs to Inactivate Viral Loadings Based upon Literature Findings

| QAC               | conc. (% w/v) | type of assay | virus tested | exposure time | quantified viral load reduction (log10) | effective viral load reduction (>99.9%)? (Y/N) | ref |
|-------------------|---------------|---------------|--------------|---------------|----------------------------------------|-----------------------------------------------|-----|
| BAC               | 0.04          | QCT           | HCoV         | 1 min         | 3.0                                    | N                                             | 20  |
| BAC, HCl          | 0.04 (pH 1.0) | QCT           | HCoV         | 1 min         | >3.0                                   | Y                                             |     |
| BAC, EtOH         | 0.04, 70      | QCT           | HCoV         | 1 min         | >3.0                                   | Y                                             |     |
| BAC               | 0.2           | suspension    | HCoV         | 10 min        | 0.0                                    | N                                             | 19  |
| BAC               | 1             | suspension    | SARS-CoV     | 5–30 min      | reduced growth; RNA still detectable by RT-PCR | Y                                             | 29  |
| Mikrobac Forte (BAC) | 0.5        | suspension    | SARS-CoV     | 30, 60 min    | ≥6.13                                  | Y                                             | 31  |
| Kohrsolin FF (BAC) | 0.5        | suspension    | SARS-CoV     | 30, 60 min    | ≥3.75                                  | Y                                             |     |
| BAC               | 0.01          | suspension    | TGEV         | 5 min         | ≥3.0                                   | Y                                             | 30  |
| CG                | 0.008         | QCT           | HCoV 229E    | 5 min         | <3.0                                   | N                                             |     |
| CG, EtOH          | 0.008, 70     | QCT           | HCoV229E     | 5 min         | ≥3.0                                   | Y                                             |     |
| mix of BAC/CB     | 0.066         | QCT           | HCoV 229E    | 10 min        | 4.0                                    | Y                                             |     |
| DDAC              | 0.0025        | suspension    | CCoV         | 3 d           | >4.0                                   | Y                                             | 28  |
| BAC               | 0.00175       | suspension    | CCoV         | 3 d           | 3.0                                    | N                                             |     |
| BAC, EtOH         | 0.1, 79       | suspension    | MHV          | 30 s          | ≥3.0                                   | Y                                             | 6   |

Additionally, two articles from 1989 and 2009 present discrepancies regarding BAC alone as well as within provided commercial formulations. For example, within the 2009 article by Dellano et al., the authors analyzed effectiveness of common household disinfectants (one being Lysol with 0.1% w/v of BAC and ≤70% ethanol) against murine hepatitis virus (MHV), a surrogate vector with structural similarities to SARS but lower biosafety level.6 They found that the BAC formulations were effective at inactivating this class of virus after only 30 s exposure (Table 1). This result was echoed in the previous 1989 article by Sattar et al. when analyzing BAC and ethanol mixtures.20 Additionally, Sattar et al. analyzed toilet bowl cleaners (with a solution of 0.04% w/v of BAC and hydrochloric acid, pH 1.0). This formulation was again proven to be effective at inactivating coronaviruses, although this lower concentration of BAC was only able to affect a 3-log reduction (99.9% reduction) in viral load in the absence of additives. Both articles point to the difficulty proving if combinatorial formulations lead to efficacy, or if the QACs aid in the viral reduction.

In addition to BAC, other commonly employed QACs such as chlorhexidine gluconate (CG, 3, Figure 2) were also examined in a 2004 editorial by Schmidt et al.30 It was found therein that CG at a concentration of 0.008% w/v was unable to reduce the viral loading of HCoV229E, but when added to 70% ethanol, reduced the viral load by 3 log10 in QCT (Table 1). In addition, the article also examined the effectiveness of combinatorial QACs (presumably CG and BAC) at a 0.066% w/v in QCTs, which proved effective after 10 min exposure, resulting in viral reduction of 4.0 log10. The only example of BAC efficacy alone in this article was with 0.01% w/v against transmissible gastroenteritis virus (TGEV), a common coronavirus known to infect pigs. Within the suspension assay, BAC reduced the viral load by 3 log10. These analyses again display the incongruity of the reports of QAC disinfectant efficacy between research laboratories.

A distinct inconsistency regarding the effectiveness of BAC is evident in a 2005 article, again by Kampf in the Journal of Hospital Infection.31 Contrary to the 2020 review, this earlier report evaluated the effectiveness of four commercially available ABHS, three surface disinfectants (two of which contained BAC at 0.5% w/v), and one instrument disinfectant (containing glutaraldehyde) against SARS-CoV. Utilizing a suspension-based assay with three different types of organic loads (0.3% serum albumin, 10% fecal calf serum, and 0.3% serum albumin/0.3% sheep erythrocytes), the study showed that each disinfectant evaluated was effective at significantly lowering the viral load across all types of organic loadings. Specifically looking at the BAC data, one formulation (Mikrobac forte) reduced the viral loading by ≥6.13 log10 while the other (Kohrsolin FP) reduced the viral loading by

---

Figure 3. Mode of action of QACs against both bacterial and viral phospholipid membranes. Red spheres represent positively charged nitrogen atoms.

Figure 4. Graph displaying reduction in viral load by various QACs. Data were obtained from Table 1. Note that QAC concentration is displayed in log10 for clarity. Data points that are listed as viral load reduction of >3.0 or <3.0 were given values of 3.2 and 2.8, respectively, to aid in clarity. Additionally, data from Ansal et al. were omitted as it did not contain viral load reduction values. An outlier from a data set (Wood et al.19) used for CDC reference is marked in red.
Despite the increasing global prevalence of the COVID-19 pandemic, the public remains unclear about the specific antiseptic effectiveness against coronaviruses. The current study assesses the effectiveness of quaternary ammonium compounds (QACs) against SARS-CoV-2 and influenza viruses, two emerging viruses of significant global concern. Both viruses belong to the family of coronaviruses, which are enveloped by phospholipid bilayers. In this study, the authors evaluated the effectiveness of QACs in disinfecting laboratory-adapted strains of murine hepatitis virus (MHV) and SARS-CoV-2, as well as influenza A and B viruses.

The study found that QACs are effective in decreasing the viral load for disinfection procedures against COVID-19 as both contain relatively similar phospholipid bilayers. Furthermore, a newer generation of multicationic QACs, such as broad-spectrum QACs (broadly QACs, BACs), is inconsistently presented across a select few papers.

In comparing the outer membranes between these and SARS-CoV-2 (Figure 5), we postulate that QACs should be effective in biorender.com. Additionally, the question remains if SARS-CoV-2 RNA is an infective agent on its own. It is plausible that QACs are successful in eradicating infectivity if only the RNA is detected after treatment. It has frequently been confirmed that QACs are effective against influenza viruses as well as both Gram-positive and Gram-negative bacterial strains. In comparing the viral envelopes (membranes) to that of bacterial membranes. Note that both influenza and SARS-CoV-2 have phospholipid membranes similar to that of mammalian phospholipids due to method of infectivity and replication. Figure made in biorender.com.

The authors declare the following competing financial interest(s): W.M.W. and K.P.C.M. have intellectual property claims on the multi-QAC compounds and their use as antiseptics.

**REFERENCES**

1. Jiang, S., Shi, Z., Shu, Y., Song, J., Gao, G. F., Tan, W., and Guo, D. (2020) A distinct name is needed for the new coronavirus. Lancet 395, 949.
2. Guarnier, J. (2020) Three Emerging Coronaviruses in Two Decades The Story of SARS, MERS, and Now COVID-19. Am. J. Clin. Pathol. 153, 420–421.
3. Gorbalyena, A. E., Baker, S. C., Baric, R. S., et al. (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544.
4. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020. World Health Organization, Mar. 2020, www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed April 27, 2020).
5. Coronavirus Map: Tracking the Global Outbreak. The New York Times, www.nytimes.com/interactive/2020/world/coronavirus-maps.html (accessed April 28, 2020).
6. Dellanno, C., Vega, Q., and Boesenberg, D. (2009) The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus. Antimicrob. Agents Chemother. 53, 649–52.
7. Rezabakhsh, A., Ala, A., and Khodaei, S. H. (2020) Novel Coronavirus (COVID-19): A New Emerging Pandemic Threat. J. Res. Clin. Med. 8, 5.
8. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020) The species Severe Acute Respiratory Syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, S36–S44.
9. Cecarelli, M., Berretta, M., Venanzii Rullo, E., Nunnari, G., and Cacopardo, B. (2020) Editorial - Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Rev. Environ. Med. Pharmacol. Sci. 24, 2781–2783.
10. Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., and Hsuheh, P. R. (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 55, 105924.
11. Wu, J. T., Leung, K., and Leung, G. M. (2020) Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395, 689–697.
